Executive Summary

The USA is forcing pharmaceutical manufacturers through the "Most-Favored-Nation" pricing rule (MFN) to tie their US drug prices to the lowest level of other wealthy countries. Roche and Novartis generate 52 and 44 percent of their pharmaceutical sales in the US and approximately 55–60 percent of their operating profits there. If US prices decline without corresponding European price increases, massive profit losses threaten the Swiss pharmaceutical industry. Switzerland exports 53 percent of its total exports (287 billion francs) in pharma, chemicals and life sciences. A Federal Council-directed process is evaluating alternative pricing models and reforms.

People

Topics

  • Drug price regulation
  • Swiss pharmaceutical industry
  • US health policy
  • Export economy

Clarus Lead

The US price pressure offensive presents Swiss pharmaceutical policy with a dilemma: the established strategy whereby high US prices finance global research while Europe benefits from discount conditions is collapsing. The commentary argues that cost containment without structural efficiency gains among all actors (hospitals, physicians, pharmacies, pharmaceutical companies) leads to worse care and less innovation in the long term. For decision-makers, the critical question becomes: which reform pathways stabilize both profits and price responsibility?

Detailed Summary

The industry's established price business model was based on Roche and Novartis being able to charge exorbitant US prices while Europe utilized state-regulated preferred pricing. Analyses by JPMorgan and Barclays show profit concentration: at Novartis, approximately 55 percent of operating core earnings (EBIT) come from US operations, at Roche nearly 60 percent. In 2025, both companies paid out more than 15 billion francs in dividends combined.

The author argues against naive expectations that profits could drop drastically without economic consequences. Reduced profits lead to lower tax payments, fewer R&D investments in Switzerland, and cut sponsorship budgets for sports and culture. The pharmaceutical industry is central to Swiss export strength: together with chemicals and life sciences responsible for 53 percent of total exports (287 billion francs) and three-quarters of export growth over the past 25 years.

Discussed reform approaches have limited effectiveness. Volume-based discount models and performance-based price adjustments (such as for cancer immunotherapies) could offer local flexibility, but may disrupt US net price calculations, as Washington has signaled it will consider net prices regardless of rebates. An MFN-compliant fund surcharge would ultimately lead to higher taxes.

The commentary advocates for systemic reforms: concessions from hospitals, physicians, pharmacies, and the basic insurance benefit catalog—not in isolation from the pharmaceutical industry. Efficiency gains under price pressure should affect all sectors, not just pharmaceuticals.

Key Findings

  • The US MFN pricing rule erodes the global price business model of Swiss pharmaceutical giants.
  • Roche and Novartis are heavily US-dependent (44–52% sales, 55–60% operating profits from USA).
  • Isolated cost cuts without efficiency reforms lead to less innovation and tax revenue.
  • Alternative pricing models (volume-based, performance-based) have limited effectiveness due to US regulation and complexity.
  • Systemic reforms must include all actors in the healthcare system.

Critical Questions

  1. Evidence/Source Validity: The JPMorgan and Barclays estimates for EBIT share are not linked to primary data from annual reports—how reliable are these analyst forecasts for profit distribution by region?

  2. Conflicts of Interest: The author argues that profit reductions automatically lead to less research—is this causality supported by empirical studies on the relationship between pharmaceutical profits and R&D spending, or is it a normative industry assumption?

  3. Causality/Alternatives: Could pharmaceutical companies reduce their cost base (e.g., management salaries, marketing budgets, administration) instead of cutting R&D—is this alternative discussed or excluded?

  4. Feasibility/Risks: The MFN-compliant fund scenario is criticized for leading to taxes—which international examples show whether such funds are practical, and how high would realistic tax requirements be?

  5. Regulatory Logic: The assumption that manufacturers will delay or forgo drug launches in Switzerland at low prices—is this based on documented behavior or hypothetical threat scenarios?

  6. Scope of Reforms: The proposal to demand concessions from "all participants" (hospitals, physicians, pharmacies)—how would this distribution issue be implemented politically, and which resistances are underestimated?

Bibliography

Primary Source: Rupen Boyadjian: Drug Prices – Switzerland Should Use US Pressure for Healthcare System Reforms – Finance and Economics (08.05.2026)

Verification Status: ✓ 08.05.2026

This text was created with the support of an AI model. Editorial Responsibility: clarus.news | Fact-Check: 08.05.2026